



## 生命科学

我们的生命科学客户面对的法律事务各有不同，因此我们灵活应变，根据客户的需求运用不同的技能。我们生命科学团队的律师不仅拥有法律、科学和医疗方面的渊博知识，更深知客户所经营业务和所处监管环境的复杂性。

当今的生物制药和医疗设备公司面临着前所未有的艰巨挑战。为了将前景看好的疗法从研发实验室推向市场，公司必须保护这些疗法免受知识产权、监管和声誉风险。此外，最近几年，来自各方面的压力与日俱增：股东要求更高的回报、因专利到期或仿制药的挑战而损失关键收入流、关键治疗领域的竞争激烈、来自医疗保健付款人的定价压力、核心安全问题以外领域的政府监管收紧、研发成本不断提高、在新兴市场提升回报面临重重挑战，以及政府加强执法力度。

我们的生命科学行业团队是规模最大、最活跃的律师事务所团队之一。我们以三十多个司法管辖区作为一个团队来运作，并将法律从业经验与渊博的行业知识融为一体，其中包括科学、医疗、监管、商业以及我们的生物制药、医疗设备和诊断客户面临的执法环境。

我们的团队包括在诉讼、合规和调查、知识产权战略和实施、并购、许可和分销、临床试验建议、隐私、外包、企业事务和反垄断等领域屡获殊荣的律师。为了有效防范风险，他们还会在必要时为客户提供各个其它领域的支持，包括政府事务、环境法律、进出口、税务、房地产和雇佣关系法律。我们的很多律师都曾是个行业的专业人士，拥有生命科学领域的博士学位或其它高级学位，还有一些律师曾经担任政府官员或检察官。

鉴于客户的需求各有差异，无论客户是大型制药公司、中型医疗设备客户或发展阶段的生物科技公司，我们会根据具体情况快速组织和安排客户服务团队。我们的团队得到国际和当地从业人员的大力支持，无论是国际交易、调查/诉讼还是跨境咨询项目，都能高效满足客户的需求。

我们专门为全球生物科学的客户创建了一个领先的人员调配、预算和账单系统，在确保团队取得佳绩的同时也为客户创造更多价值。

我们的生命科学团队每天都在帮助客户解决他们最艰巨的挑战。这些事务包括：

- 在中国开展敏感调查
- 在拉丁美洲磋商复杂的多国分销交易
- 在美国的一宗大规模侵权案中担任国家法律顾问
- 帮助出售或收购主要业务资产
- 就透明度法律的实施或其它新法律的影响提供咨询服务
- 为关键产品制定风险降低计划
- 与一家全球非政府组织磋商一宗大额疫苗合约

### Marco de Morpurgo

合伙人  
罗马  
电话: +39 06 68 880 1  
marco.demorpurgo@dlapiper.com

### Andrew P. Gilbert

合伙人  
新泽西(肖特山)  
电话: +1 973 520 2553  
andrew.gilbert@dlapiper.com

### Matt Holian

合伙人  
波士顿  
电话: +1 617 406 6009  
matt.holian@dlapiper.com

- Antitrust and Competition
- 公司
- 雇佣关系
- 知识产权与技术
- 国际税务顾问
- 诉讼、仲裁和调查
- 房地产
- 税务
- Corporate Disputes

- 为一项多司法管辖区临床试验提供咨询服务
- 就欧洲区的裁员行动提供咨询服务
- 为全球业务行为和合规职能提供支援服务
- 外包关键的研发或信息技术职能
- 为前景看好的新疗法制定知识产权战略
- 磋商覆盖全球的许可和协作交易
- 在专利诉讼中保护一种重磅药物

## Sustainability and ESG

---

Sustainability and resilience are core business issues in the life sciences sector, given the sector's central role in addressing systemic global challenges including pandemics, access to medicine, and fundamental human rights. Although the specific factors from a sustainability, environmental, social and governance (ESG) perspective in the life science industry differ from those of other industries, creating new and sustainable value in the life science space will depend upon how companies address relevant ESG risks. Boards must actively identify such ESG risks and ensure that they are efficiently mitigated in order for their companies to avoid pitfalls and ensure compliance with evolving regulation around the globe – and also to maintain their competitive position and profitability.

On the basis of our experience in the sector, we believe the following sustainability-related themes to be the core ESG issues that will continue to affect life science businesses:

- **Access and affordability:** Addressing unmet healthcare needs, increasing access to affordable essential medicines and strengthening health systems around the world are all fundamental to social and economic progress. The coronavirus disease 2019 (COVID-19) has further highlighted the importance of the life sciences sector in addressing these challenges. Against this background, international life science business will need to engage in discussions about and develop strategies addressing these issues across the world, particularly with regard to improving the situation in lesser developed countries.
- **Supply chain compliance:** Many governments and regulators around the world are implementing tighter rules on supply chain compliance. To retain their license to operate, life sciences companies must adhere to an evolving set of global laws and regulations. Furthermore, transparency requirements, as well as responsibility and liability for global suppliers are increasing. This ongoing regulatory shift, and the increased likelihood of litigation which goes with it, will have a significant impact on the global life sciences industry. This is because supply chains are often particularly lengthy and complex and influenced by many different internal and external factors that are hard to monitor and control.
- **Product safety and quality:** Fake or substandard medicines lead to hundreds of thousands of deaths each year. Drug safety, along with protecting health consumers from counterfeit medicines and drug diversion, are integral to ensuring public health and maintaining trust and confidence in the life sciences sector. Consequently, life science companies will need to put increasing focus on ensuring product safety as well as maintaining secure distribution channels to patients.
- **Business ethics:** There is increasing stakeholder attention, including from regulators and policymakers and also from providers of capital, on transparency and ethics in business dealings with healthcare providers and medical practitioners for the sale and use of products, as well as in relation to lobbying and advocacy activities. The way in which businesses respond to these expectations can have a direct impact upon their reputation, their cost of capital and ultimately upon their license to operate.
- **Transparency and access in clinical trials:** Stakeholders increasingly expect transparency in clinical trials and wider access to trial data for scientific exchange and research. There is a bright spotlight on participant safety and privacy. Businesses are demanding more effective information sharing to enable informed decision-making and consent, along with post-trial access to results. Technology and collaborative partnerships with patient and health worker groups enable wider representative demographic populations to participate in clinical trials.
- **Sustainable sourcing, product lifecycles and a circular economy:** Markets demand greater visibility across product lifecycles, businesses make commitments to net-zero decarbonisation and business model innovation is driven by circular economy concepts. Underpinned by an increasingly complex transnational regulatory landscape, these developments are changing the way raw materials are sourced; how products are designed, manufactured, packaged, sold, reused or recycled; how waste and hazardous material is treated; and how wider environmental and social impacts relating to issues like emissions, plastics, water use, biodiversity loss, labour conditions and community impacts are managed.
- **Net-zero decarbonisation and optimisation of processes:** In striving to decarbonise the economy, businesses are implementing commitments to Science Based Targets, increasing energy efficiency and reducing carbon output, decreasing dependency on fossil fuels and increasing the use of renewables. The implementation of these initiatives is creating operational efficiencies, optimising the drug manufacturing, packaging and distribution process and reducing costs across the sector.

To discuss the implications of these issues for your business, please contact our ESG leaders.



## 生命科学

我们的生命科学客户面对的法律事务各有不同，因此我们灵活应变，根据客户的需求运用不同的技能。我们生命科学团队的律师不仅拥有法律、科学和医疗方面的渊博知识，更深知客户所经营业务和所处监管环境的复杂性。

当今的生物制药和医疗设备公司面临着前所未有的艰巨挑战。为了将前景看好的疗法从研发实验室推向市场，公司必须保护这些疗法免受知识产权、监管和声誉风险。此外，最近几年，来自各方面的压力与日俱增：股东要求更高的回报、因专利到期或仿制药的挑战而损失关键收入流、关键治疗领域的竞争激烈、来自医疗保健付款人的定价压力、核心安全问题以外领域的政府监管收紧、研发成本不断提高、在新兴市场提升回报面临重重挑战，以及政府加强执法力度。

我们的生命科学行业团队是规模最大、最活跃的律师事务所团队之一。我们以三十多个司法管辖区作为一个团队来运作，并将法律从业经验与渊博的行业知识融为一体，其中包括科学、医疗、监管、商业以及我们的生物制药、医疗设备和诊断客户面临的执法环境。

我们的团队包括在诉讼、合规和调查、知识产权战略和实施、并购、许可和分销、临床试验建议、隐私、外包、企业事务和反垄断等领域屡获殊荣的律师。为了有效防范风险，他们还会在必要时为客户提供各个其它领域的支持，包括政府事务、环境法律、进出口、税务、房地产和雇佣关系法律。我们的很多律师都曾是各个行业的专业人士，拥有生命科学领域的博士学位或其它高级学位，还有一些律师曾经担任政府官员或检察官。

鉴于客户的需求各有差异，无论客户是大型制药公司、中型医疗设备客户或发展阶段的生物科技公司，我们会根据具体情况快速组织和安排客户服务团队。我们的团队得到国际和当地从业人员的大力支持，无论是国际交易、调查/诉讼还是跨境咨询项目，都能高效满足客户的需求。

我们专门为全球生物科学的客户创建了一个领先的人员调配、预算和账单系统，在确保团队取得佳绩的同时也为客户创造更多价值。

我们的生命科学团队每天都在帮助客户解决他们最艰巨的挑战。这些事务包括：

- 在中国开展敏感调查
- 在拉丁美洲磋商复杂的多国分销交易
- 在美国的一宗大规模侵权案中担任国家法律顾问
- 帮助出售或收购主要业务资产
- 就透明度法律的实施或其它新法律的影响提供咨询服务
- 为关键产品制定风险降低计划
- 与一家全球非政府组织磋商一宗大额疫苗合约
- 为一项多司法管辖区临床试验提供咨询服务

- 就欧洲区的裁员行动提供咨询服务
- 为全球业务行为和合规职能提供支援服务
- 外包关键的研发或信息技术职能
- 为前景看好的新疗法制定知识产权战略
- 磋商覆盖全球的许可和协作交易
- 在专利诉讼中保护一种重磅药物

## Sustainability and ESG

---

Sustainability and resilience are core business issues in the life sciences sector, given the sector's central role in addressing systemic global challenges including pandemics, access to medicine, and fundamental human rights. Although the specific factors from a sustainability, environmental, social and governance (ESG) perspective in the life science industry differ from those of other industries, creating new and sustainable value in the life science space will depend upon how companies address relevant ESG risks. Boards must actively identify such ESG risks and ensure that they are efficiently mitigated in order for their companies to avoid pitfalls and ensure compliance with evolving regulation around the globe – and also to maintain their competitive position and profitability.

On the basis of our experience in the sector, we believe the following sustainability-related themes to be the core ESG issues that will continue to affect life science businesses:

- **Access and affordability:** Addressing unmet healthcare needs, increasing access to affordable essential medicines and strengthening health systems around the world are all fundamental to social and economic progress. The coronavirus disease 2019 (COVID-19) has further highlighted the importance of the life sciences sector in addressing these challenges. Against this background, international life science business will need to engage in discussions about and develop strategies addressing these issues across the world, particularly with regard to improving the situation in lesser developed countries.
- **Supply chain compliance:** Many governments and regulators around the world are implementing tighter rules on supply chain compliance. To retain their license to operate, life sciences companies must adhere to an evolving set of global laws and regulations. Furthermore, transparency requirements, as well as responsibility and liability for global suppliers are increasing. This ongoing regulatory shift, and the increased likelihood of litigation which goes with it, will have a significant impact on the global life sciences industry. This is because supply chains are often particularly lengthy and complex and influenced by many different internal and external factors that are hard to monitor and control.
- **Product safety and quality:** Fake or substandard medicines lead to hundreds of thousands of deaths each year. Drug safety, along with protecting health consumers from counterfeit medicines and drug diversion, are integral to ensuring public health and maintaining trust and confidence in the life sciences sector. Consequently, life science companies will need to put increasing focus on ensuring product safety as well as maintaining secure distribution channels to patients.
- **Business ethics:** There is increasing stakeholder attention, including from regulators and policymakers and also from providers of capital, on transparency and ethics in business dealings with healthcare providers and medical practitioners for the sale and use of products, as well as in relation to lobbying and advocacy activities. The way in which businesses respond to these expectations can have a direct impact upon their reputation, their cost of capital and ultimately upon their license to operate.
- **Transparency and access in clinical trials:** Stakeholders increasingly expect transparency in clinical trials and wider access to trial data for scientific exchange and research. There is a bright spotlight on participant safety and privacy. Businesses are demanding more effective information sharing to enable informed decision-making and consent, along with post-trial access to results. Technology and collaborative partnerships with patient and health worker groups enable wider representative demographic populations to participate in clinical trials.
- **Sustainable sourcing, product lifecycles and a circular economy:** Markets demand greater visibility across product lifecycles, businesses make commitments to net-zero decarbonisation and business model innovation is driven by circular economy concepts. Underpinned by an increasingly complex transnational regulatory landscape, these developments are changing the way raw materials are sourced; how products are designed, manufactured, packaged, sold, reused or recycled; how waste and hazardous material is treated; and how wider environmental and social impacts relating to issues like emissions, plastics, water use, biodiversity loss, labour conditions and community impacts are managed.
- **Net-zero decarbonisation and optimisation of processes:** In striving to decarbonise the economy, businesses are implementing commitments to Science Based Targets, increasing energy efficiency and reducing carbon output, decreasing dependency on fossil fuels and increasing the use of renewables. The implementation of these initiatives is creating operational efficiencies, optimising the drug manufacturing, packaging and distribution process and reducing costs across the sector.

---

To discuss the implications of these issues for your business, please contact our ESG leaders.